Current Status of Cagrisema Trials
Cagrisema, Novo Nordisk's investigational combo of cagrilintide and semaglutide for obesity and type 2 diabetes, has ongoing Phase 3 trials like REDEFINE, but none are scheduled to start or report primary results in 2026 based on ClinicalTrials.gov data as of late 2024. Most active trials (e.g., NCT05567796 for weight management) have primary completion dates in 2025.[1]
Planned Trial Timelines into 2026
No new Phase 3 or pivotal trials for cagrisema are listed to initiate in 2026. Existing REDEFINE program trials, such as REDEFINE 1 (NCT05567740) and REDEFINE 2 (NCT05567727), target primary completion by late 2025, with some follow-up extending into 2026 for secondary endpoints like cardiovascular outcomes. Novo Nordisk has not announced fresh trial starts for 2026; focus remains on completing current studies for regulatory filings expected in 2025.[1][2]
What Happens After 2025 Trials?
If REDEFINE data succeeds, Novo Nordisk plans U.S. and EU approvals in 2025, potentially shifting 2026 efforts to post-marketing studies or expanded access trials rather than new de novo trials. A long-term outcomes trial (e.g., NCT05995480) runs through 2031, overlapping 2026 but not new.[1]
Comparison to Other Novo Nordisk Programs
Unlike cagrisema, Novo Nordisk's amycretin (oral GLP-1/GIP) has Phase 2 trials wrapping in 2025 with Phase 3 possibly starting 2026. Cagrisema's timeline aligns more with liraglutide/wegovy extensions, prioritizing regulatory hurdles over new trials.[2]
[1]: ClinicalTrials.gov search for cagrisema
[2]: Novo Nordisk pipeline update, Q3 2024